The effects of 2*-fucosyllactose and resistant starch on acetate production and human substrate metabolism

The effects of 2*-fucosyllactose and resistant starch on acetate production and human substrate metabolism - 2*-fucosyllactose and acetate production in vivo

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON55195

Enrollment

Registered

2019-12-18

Start date

2020-02-04

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lipid metabolism overweight

Interventions

The day before each visit, participants consume one of the supplements with standardized meals: 1. Placebo: 11.43 g (3 x 3.81 g) maltodextrin Glucidex IT 12 (Roquette Freres, Lestrem, France) (43.4

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Twelve lean (BMI * 20kg/m2 and * 24.9kg/m2) healthy men aged 30 * 65 years and 12 overweight/obese (BMI * 25kg/m2 and * 34.9kg/m2) prediabetic men aged between 30 * 65 years.

Exclusion criteria

Exclusion criteria: - Type 2 diabetes mellitus - Gastroenterological diseases or abdominal surgery; - Cardiovascular diseases, cancer, liver or kidney malfunction, disease with a life expectancy shorter than 5 years; - Abuse of products; alcohol and drugs, excessive nicotine use defined as >20 cigarettes per day; - Plans to lose weight or following of a hypocaloric diet; - Regular supplementation of pre- or probiotic products, use of pre- or probiotics 3 months prior to the start of the study; - Intensive exercise training more than three hours a week; - Use of any medication that influences glucose or fat metabolism and inflammation (i.e. NSAIDs); - Regular use of laxation products; - Use of antibiotics in the last three months .

Design outcomes

Primary

Measure	Time frame
Plasma and faecal acetate and other SCFA (ie. butyrate, propionate) concentrations.	—

Secondary

Measure	Time frame
- Energy expenditure, fat and carbohydrate oxidation will be measured using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands); - Circulating hormone concentrations (Insulin, GLP-1, PYY) - Circulating metabolite concentrations (Glucose, Free Fatty Acids); - Appetite (Visual Analog Scales (VAS)-scoring system for hunger and satiety). - Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK). - Faecal microbiota composition (16S RNA) - Three-day food record. A three-day food record will be completed three days prior to each CID. - Gastrointestinal Symptom Rating Scale (GSRS) questionnaire.	—

Measure

Time frame

- Energy expenditure, fat and carbohydrate oxidation will be measured using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands); - Circulating hormone concentrations (Insulin, GLP-1, PYY) - Circulating metabolite concentrations (Glucose, Free Fatty Acids); - Appetite (Visual Analog Scales (VAS)-scoring system for hunger and satiety). - Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK). - Faecal microbiota composition (16S RNA) - Three-day food record. A three-day food record will be completed three days prior to each CID. - Gastrointestinal Symptom Rating Scale (GSRS) questionnaire.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)